Literature DB >> 17192790

Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma.

Yasufumi Kato1, Koji Tsuta, Kunihiko Seki, Akiko Miyagi Maeshima, Shunichi Watanabe, Kenji Suzuki, Hisao Asamura, Ryosuke Tsuchiya, Yoshihiro Matsuno.   

Abstract

The separation of benign reactive mesothelium (RM) from malignant mesothelial proliferation can be a major challenge. A number of markers have been proposed, including epithelial membrane antigen, p53 protein, and P-glycoprotein. To date, however, no immunohistochemical marker that allows unequivocal discrimination of RM from malignant pleural mesothelioma (MPM) has been available. A family of glucose transporter isoforms (GLUT), of which GLUT-1 is a member, facilitate the entry of glucose into cells. GLUT-1 is largely undetectable by immunohistochemistry in normal epithelial tissues and benign tumors, but is expressed in a variety of malignancies. Thus, the expression of GLUT-1 appears to be a potential marker of malignant transformation. Recently, in fact, some studies have shown that GLUT-1 expression is useful for distinguishing benign from malignant lesions. The purpose of the present study was to evaluate the diagnostic utility of GLUT-1 expression for diagnostic differentiation between RM and MPM. Immunohistochemical staining for GLUT-1 was performed in 40 cases of RM, 48 cases of MPM, and 58 cases of lung carcinoma. Immunohistochemical GLUT-1 expression was seen in 40 of 40 (100%) MPMs, and in all cases the expression was demonstrated by linear plasma membrane staining, sometimes with cytoplasmic staining in addition. GLUT-1 expression was also observed in 56 out of 58 (96.5%) lung carcinomas. On the other hand, no RM cases were positive for GLUT-1. GLUT-1 is a sensitive and specific immunohistochemical marker enabling differential diagnosis of RM from MPM, whereas it cannot discriminate MPM from lung carcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17192790     DOI: 10.1038/modpathol.3800732

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  20 in total

1.  Increased Expression of the Glucose Transporter Type 1 Gene Is Associated With Worse Overall Survival in Resected Pancreatic Adenocarcinoma.

Authors:  Ashley H Davis-Yadley; Andrea M Abbott; Jose M Pimiento; Dung-Tsa Chen; Mokenge P Malafa
Journal:  Pancreas       Date:  2016-08       Impact factor: 3.327

Review 2.  The legacy of the F344 rat as a cancer bioassay model (a retrospective summary of three common F344 rat neoplasms).

Authors:  Robert R Maronpot; Abraham Nyska; Jennifer E Foreman; Yuval Ramot
Journal:  Crit Rev Toxicol       Date:  2016-06-09       Impact factor: 5.635

3.  Adenomatoid tumors of the female and male genital tract. A comparative clinicopathologic and immunohistochemical analysis of 47 cases emphasizing their site-specific morphologic diversity.

Authors:  David L Wachter; Peter H Wünsch; Arndt Hartmann; Abbas Agaimy
Journal:  Virchows Arch       Date:  2011-02-20       Impact factor: 4.064

4.  Immunohistochemical profile of normal mesothelium and histiocytic/methothelial hyperplasia: a case report.

Authors:  Tadashi Terada
Journal:  Int J Clin Exp Pathol       Date:  2011-08-14

Review 5.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

6.  GLUT-1 expression in pancreatic neoplasia: implications in pathogenesis, diagnosis, and prognosis.

Authors:  Olca Basturk; Rajendra Singh; Ecmel Kaygusuz; Serdar Balci; Nevra Dursun; Nil Culhaci; N Volkan Adsay
Journal:  Pancreas       Date:  2011-03       Impact factor: 3.327

7.  β-catenin expression in benign and malignant pleural disorders.

Authors:  Waseem Anani; Richard Bruggeman; Dani S Zander
Journal:  Int J Clin Exp Pathol       Date:  2011-10-30

Review 8.  Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review.

Authors:  Rossella Bruno; Greta Alì; Gabriella Fontanini
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

9.  Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion.

Authors:  S Tsuji; Y Tsuura; T Morohoshi; T Shinohara; F Oshita; K Yamada; Y Kameda; T Ohtsu; Y Nakamura; Y Miyagi
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

10.  Expression of p-AKT characterizes adenoid cystic carcinomas of head and neck with a higher risk for tumor relapses.

Authors:  Hans-Ullrich Völker; Matthias Scheich; Annette Berndt; Imme Haubitz; Alexandra Metzger; Hans-Konrad Müller-Hermelink; Ulrike Kämmerer; Melanie Schmidt
Journal:  Diagn Pathol       Date:  2009-06-19       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.